Bio-Techne Beheer

Beheer criteriumcontroles 2/4

De CEO Bio-Techne is Kim Kelderman, benoemd in Feb2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.85M, bestaande uit 11.1% salaris en 88.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde R$ 16.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 7.8 jaar.

Belangrijke informatie

Kim Kelderman

Algemeen directeur

US$6.9m

Totale compensatie

Percentage CEO-salaris	11.1%
Dienstverband CEO	less than a year
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kim Kelderman's beloning veranderd ten opzichte van Bio-Techne's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$151m
Jun 30 2024	US$7m	US$760k	US$168m
Mar 31 2024	n/a	n/a	US$203m
Dec 31 2023	n/a	n/a	US$224m
Sep 30 2023	n/a	n/a	US$247m
Jun 30 2023	US$3m	US$590k	US$285m
Mar 31 2023	n/a	n/a	US$271m
Dec 31 2022	n/a	n/a	US$262m
Sep 30 2022	n/a	n/a	US$292m
Jun 30 2022	US$3m	US$562k	US$272m
Mar 31 2022	n/a	n/a	US$225m
Dec 31 2021	n/a	n/a	US$210m
Sep 30 2021	n/a	n/a	US$177m
Jun 30 2021	US$4m	US$530k	US$140m
Mar 31 2021	n/a	n/a	US$184m
Dec 31 2020	n/a	n/a	US$175m
Sep 30 2020	n/a	n/a	US$248m
Jun 30 2020	US$2m	US$500k	US$229m
Mar 31 2020	n/a	n/a	US$187m
Dec 31 2019	n/a	n/a	US$195m
Sep 30 2019	n/a	n/a	US$93m
Jun 30 2019	US$2m	US$452k	US$96m
Mar 31 2019	n/a	n/a	US$121m
Dec 31 2018	n/a	n/a	US$96m
Sep 30 2018	n/a	n/a	US$128m
Jun 30 2018	US$2m	US$73k	US$126m

Compensatie versus markt: De totale vergoeding ($USD 6.85M ) Kim } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 5.73M ).

Compensatie versus inkomsten: De beloning van Kim is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Kim Kelderman (57 yo)

less than a year

Tenure

US$6,852,495

Compensatie

Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kim Kelderman	CEO, President & Director	less than a year	US$6.85m	0.025% R$ 17.0m
James Hippel	Executive VP of Finance & CFO	10.6yrs	US$5.20m	0.067% R$ 46.4m
Shane Bohnen	Senior VP	1.7yrs	US$1.46m	0.0011% R$ 733.0k
William Geist	President of Protein Sciences Segment	2.8yrs	US$3.65m	0.0070% R$ 4.8m
Matthew McManus	President of Diagnostics & Genomics	less than a year	US$2.27m	geen gegevens
Gary Latham	VP & CTO	less than a year	geen gegevens	geen gegevens
David Clair	Senior Director of Investor Relations & Corporate Development	no data	geen gegevens	geen gegevens
Gerry Andros	Vice President of Sales and Marketing	no data	geen gegevens	geen gegevens
Martin Wirtz	Senior Vice President of Strategy & Corporate Development	less than a year	geen gegevens	geen gegevens
Cheryl Bethune	Senior VP & Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Luca Cicchetti	Managing Director	8.3yrs	geen gegevens	geen gegevens
Steve Crouse	Senior Vice President of Analytical Solutions Division	1.8yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van T1CH34 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kim Kelderman	CEO, President & Director	1.8yrs	US$6.85m	0.025% R$ 17.0m
Robert Baumgartner	Independent Chairman of the Board	21.8yrs	US$410.46k	0.028% R$ 19.5m
John Higgins	Independent Director	15.5yrs	US$300.46k	0.030% R$ 21.0m
Joseph Keegan	Independent Director	7.8yrs	US$275.46k	0.0087% R$ 6.0m
Roeland Nusse	Independent Director	14.5yrs	US$290.46k	0.028% R$ 19.4m
Julie Bushman	Independent Director	4.3yrs	US$291.50k	0.0045% R$ 3.1m
John Denu	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sachdev Sidhu	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
S. J. Vessey	Independent Director	5.4yrs	US$275.46k	0.0059% R$ 4.1m
Alpna Seth	Independent Director	7.8yrs	US$275.46k	0.0087% R$ 6.0m
David Artis	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Judith Klimovsky	Independent Director	less than a year	US$113.73k	0.0014% R$ 933.6k

7.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van T1CH34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Bio-Techne Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024

Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors

Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024

Bio-Techne Corporation Announces Executive Changes

Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023

Bio-Techne Corporation Announces Executive Changes, Effective March 3, 2023

Recent updates

Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo

Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting

Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024

ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies

Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024

Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2024, Payable on August 30, 2024

Bio-Techne Corporation Announces the Launch of the Leo™ System

Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024

Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors

Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay

Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024

Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow

Bio-Techne Corporation to Report Q2, 2024 Results on Feb 01, 2024

Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024

Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended September 30, 2023, Will Be Payable November 24, 2023

Bio-Techne Corporation to Present New Data Using Lunaphore's Comet Technology at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Bio-Techne Corporation Announces Executive Changes

Bio-Techne Corporation Launches the New Maurice Chromeleon Driver Kit, Which Enables Control of its Maurice™ Instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System

Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023

Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others.

Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA.

Bio-Techne Corporation Announces Launch of Kappa and Lambda Rnascope Ish Probes as Analyte Specific Reagents (Asrs) for the Detection of Immunoglobulin Kappa and Lambda Light Chains mRNA

Bio-Techne Declares Quarterly Dividend, Payable May 26, 2023

Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2022, Payable on February 27, 2023

Bio-Techne Corporation Announces Executive Changes, Effective March 3, 2023

Bio-Techne Launches the Mauriceflex™ System, Adding Cief Fractionation Capability to the Gold Standard Maurice Assays

Bio-Techne Corporation Launches RNAscope Plus Assay to Advance Gene Therapy Development

Bio-Techne Releases MitoBrilliant Fluorescent Dyes, Providing A Next-Generation Tool for Imaging Mitochondria in Live and Fixed Cells

Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2022, Payable on November 28, 2022

Bio-Techne Corporation Announces the Introduction of 3 Novel TSA Vivid Fluorophores for Highly Sensitive Fluorescent Detection of RNAs and Proteins in Cells and Tissues

Bio-Techne Corporation and PROGEN Introduce New Simple Plex AAV Viral Titer Assays

Bio-Techne Corporation Commercializes Automated Multi-Omic Rnascope Assays for Spatial Visualization of RNA and Protein Biomarkers in FFPE Tissues

Bio-Techne Corporation, Annual General Meeting, Oct 27, 2022

Bio-Techne Corporation Announces Release of Quantist Luminex Data Analysis Software

Bio-Techne Corporation Announces Dividend for the Quarter Ended June 30, 2022, Payable on August 29, 2022

Bio-Techne Launches New Turbo CE-SDS ™ Cartridge, Accelerating Protein Purity Analysis Throughput by 400%

Bio-Techne Announces Launch of the CE-IVD RNAscope ISH Probe High Risk HPV Assay for Head and Neck Cancer

Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Namocell, Inc.

Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Growth-Defensive Index

Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Namocell, Inc.

Bio-Techne Corporation Announces the Publication of A Global Study in the Journal of Electrophoresis

Bio-Techne Corporation Declares Quarterly Dividend for the Quarter Ended March 31, 2022, Payable on May 27, 2022

Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay

Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2021, Payable on February 25, 2022

Bio-Techne Corporation Announces Commercial Release of High Sensitivity Fluorescent Detection Stellar NIR / IR™ Modules for Jess Automated Western Blotting System

Bio-Techne Launches ExCellerate iPSC Expansion Medium

Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000E Value Index

Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Value-Defensive Index

Bio-Techne Corporation Announces Results of A Multisite Evaluation Study of the AmplideX

Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2021, Payable on May 28, 2021

Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations

Bio-Techne Corporation (NasdaqGS:TECH) has reached an agreement to acquire Asuragen, Inc for $320 million.

Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana

Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne's Tcbuster™ for the Development of Luminary's Car-T Cell Therapies

Bio-Techne Corporation Announces That the U.S. Food and Drug Administration Added Covid-Seroklir to the Emergency Use Authorization

Bio-Techne Corporation Announces Expanded Simple Plex Immunoassay Cartridge Portfolio

Bio-Techne, Fresenius Kabi, and Wilson Wolf Launches A Joint Venture Scaleready

Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development

Kantaro Biosciences, LLC, Joint Venture Between Mount Sinai Health System and RenalytixAI, and Partner Bio-Techne Corporation Receive CE Marking for COVID-SeroKlir and COVID-SeroIndex

Bio-Techne Corporation Announces Commercial Release of New SARS-CoV-2 Multi-Antigen Serology Assay Kit for Simple Western

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur